Recombinant Interferon Alfa-2b + Rintatolimod
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 14/100
14
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic and Lymphoid Cell Neoplasm
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Trial Timeline
Nov 17, 2020 → Mar 15, 2023
NCT ID
NCT04379518About Recombinant Interferon Alfa-2b + Rintatolimod
Recombinant Interferon Alfa-2b + Rintatolimod is a phase 1/2 stage product being developed by AIM ImmunoTech for Hematopoietic and Lymphoid Cell Neoplasm. The current trial status is terminated. This product is registered under clinical trial identifier NCT04379518. Target conditions include Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed.
What happened to similar drugs?
1 of 3 similar drugs in Hematopoietic and Lymphoid Cell Neoplasm were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
9
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04379518 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Hematopoietic and Lymphoid Cell Neoplasm